P2RY12 and Abnormal renal physiology: Though it seems logical to presume benefit to longer duration of dual antiplatelet therapy in diabetic patients with renal dysfunction due to their increased risk of thrombosis and resistance to P2Y12 inhibitors, among diabetic patients with renal dysfunction in the present study, dual antiplatelet therapy duration after PCI (less than 12 months vs. more than 12 months) did not show any statistically significant difference on the incidence of ST.